Godwin, Colin D. published the artcileThe Bruton′s tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity, Application of SU6656, the publication is British Journal of Haematology (2020), 189(1), e9-e13, database is CAplus and MEDLINE.
This study examined the abrogation of bispecific antibody (BiAb)-mediated T-cell cytotoxicity by Bruton′s tyrosine kinase inhibitor (BTKi) ibrutinib. Results suggests that ibrutinib-mediated inhibition of BiAb-mediated cancer cell killing is due to an inhibitory effect on T-cell effector function rather than induction of leukemia cell resistance. Together, the studies indicate acute exposure to BTKi impairs T-cell activation and lysis of target cells upon treatment with CD3-directed BiAbs, at least partially due to effects that are independent of BTK inhibition. Further mechanistic studies will be necessary to identify which signaling pathways are involved in this inhibitory effect of BTKi.
British Journal of Haematology published new progress about 330161-87-0. 330161-87-0 belongs to indole-building-block, auxiliary class Protein Tyrosine Kinase/RTK,Src, name is SU6656, and the molecular formula is C19H21N3O3S, Application of SU6656.
Referemce:
https://www.nature.com/articles/s41429-020-0333-2,
Preparation of Indole Containing Building Blocks for the Regiospecific Construction of Indole Appended Pyrazoles and Pyrroles